Brief Article
Copyright ©2010 Baishideng.
World J Gastroenterol. Feb 14, 2010; 16(6): 770-777
Published online Feb 14, 2010. doi: 10.3748/wjg.v16.i6.770
Table 1 Characteristics of 9 included studies
StudyCountry or regionPatients
Study design
GenderAge (yr)
Lin[16], 1995Taiwan, China29M, 11F6.2 ± 2.4RCT (3 score)
Bhimma et al[17], 2002South Africa34M, 5F8.7, 9.2Cohort study
Lai et al[18], 1991Hong Kong, China14M, 2F27.2 ± 6.2Cohort study
Tang et al[19], 2005Hong Kong, China14M, 8F48.3 ± 12.8, 43.1 ± 22.8Cohort study
Panomsak et al[20], 2006Thailand14M, 10F39.8Cohort study
Yang et al[21], 2003Wenzhou, China28M, 5F8.01 ± 1.23Cohort study
Lai et al[22], 1990Hong Kong, China10M, 5F22.8 ± 14.4, 17.2 ± 8.2Cohort study
Ozdamar et al[23], 2003Turkey11M, 3F10Cohort study
Peña et al[24], 2001Spain11M, 1F4.52 ± 2.34Cohort study
Table 2 Design of 6 clinical trials on efficacy of antiviral therapy for HBV-GN
AuthorGroupCase (n)InterventionDropped-out (n)Outcome
Follow-up
CRVRRenal insufficiency (n)
Lin[16], 1995Control20The same supportive treatment as treatment group07 complete remission, 10 partial remission0 HBeAg clearanceUA24 mo
Treatment20rIFNα, 5 mU (weight < 20 kg), 8 mU (weight ≥ 20 kg), 3 t/w for 12 mo020 complete remission16 HBeAg clearanceUA
Bhimma et al[17], 2002Control20Anti-hypertension and diuretics if needed00 complete remission, 5 partial remission1 HBeAg clearance040 wk
Treatment24rIFNα-2b, 10 mU/m2, 3 t/w for 16 wk510 complete remission, 4 partial remission10 HBeAg clearance, 4 reverters, 5 failures2
Lai et al[18], 1991Control11Diuretic agents or dipyridamole or none00 complete remission, 8 partial remission0 HBeAg clearance460 mo
Treatment52 wk of prednisolone 40 mg/d followed by 12 wk of rIFNα-2b 3 mU, 3 t/w01 complete remission, 4 partial remission1 HBeAg seroconversion1
Tang et al[19], 2005Control12ACEI or ARB02 complete remission, 2 partial remission1 HBeAg clearance, 2 HBeAg seroconversion5 ESRD49.2 ± 16.5 mo
Treatment103TC, 100 mg/d, 49.2 ± 16.5 mo, plus ACEI or ARB07 complete remission, 3 partial remission8 HBV-DNA clearance (5 HBeAg clearance)0
Panomsak et al[20], 2006Control10ACEI, fish oil, or neither32 complete remission0 HBeAg clearance2 ESRD5-120 mo
Treatment71 month of prednisolone followed by 3TC in 6 case and IFNα in one case02 complete remission, 5 partial remission1 HBeAg seroconversion0
Yang et al[21], 2003Control14The supportive or symptomatic treatment09 complete remission, 2 partial remission3 HBeAg seroconversion03.8 ± 2.4 yr
Treatment6rIFNα, 1-3 mU, 3 t/w for 3-6 mo03 complete remission, 2 partial remission3 HBeAg seroconversion0
Table 3 Design of 5 clinical trials on efficacy of corticosteroid therapy for HBV-GN
AuthorGroupCase (n)InterventionDropped-out (n)Outcome
Follow-up
CRRenal insufficiency (n)
Lai et al[22], 1990Control7Diuretic agents02 complete remissionUA14-37 mo
Treatment8Prednisolone 60 mg/d (adult), 40 mg/m2 per day (< 15 yr), for 6 mo03 complete remission, 4 partial remission, 1 relapseUA
Ozdamar et al[23], 2003Control4None04 complete remissionUA5-120 mo
Treatment8Prednisolone, 2 mg/kg per day21 complete remission, 4 partial remission, 1 death due to sepsisUA
Panomsak et al[20], 2006Control10ACEI, fish oil, or neither32 complete remission2 ESRD5-120 mo
Treatment6Prednisolone, 2 mg/kg per day13 complete remission, 2 partial remission0
Yang et al[21], 2003Control14The same supportive and symptomatic treatment as treatment group09 complete remission, 2 partial remission03.8 ± 2.4 yr
Treatment8Prednisolone, 1.5-2 mg/kg per day, for 3 mo04 complete remission, 2 partial remission0
Peña et al[24], 2001Control4Symptomatic treatment04 complete remissionUA9.95 ± 5.88 yr
Treatment7Prednisone, 1.5-2 mg/kg per day, a minimun of 4 wk (1 case prednisone + CTX)07 steroid-resistant during therapy, but all complete remission at the end of follow-upUA